Loading: 100%
Acadia Pharmaceuticals Inc logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 420 (as per Q1 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker ACADno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 172025303540
datesClosing price (adj.)
13.10.201735.40
11.10.201735.76
04.10.201739.14
27.09.201737.90
20.09.201736.85
13.09.201736.46
06.09.201735.69
30.08.201734.72
23.08.201731.91
16.08.201731.39
09.08.201733.21
02.08.201729.49
26.07.201730.13
19.07.201729.00
12.07.201727.95
05.07.201729.64
27.06.201727.64
20.06.201728.22
13.06.201727.25
06.06.201726.16
30.05.201725.65
23.05.201727.55
16.05.201728.40
09.05.201732.26
02.05.201732.77
25.04.201734.71
18.04.201732.44
11.04.201732.90
04.04.201733.53
28.03.201735.71
21.03.201735.01
14.03.201737.53
07.03.201736.21
28.02.201738.11
21.02.201739.20
14.02.201739.69
07.02.201738.19
31.01.201734.59
24.01.201730.14
17.01.201731.35
10.01.201731.47
03.01.201728.77
27.12.201628.95
19.12.201625.43
12.12.201625.28
05.12.201627.79
28.11.201627.33
21.11.201628.63
14.11.201629.06
07.11.201622.99
31.10.201623.31
24.10.201623.72
17.10.201624.33
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
35.40n/a
Market Capitalisation
in million USD
4,320n/a
Enterprise Value
in million USD
3,851n/a
Common Shares Outstanding
as per May 3, 2017
122,046,442n/a
Preferred Shares Outstanding
as per May 3, 2017
n/a
Average Basic Shares Outstanding
TTM
118,434,250n/a
Average Diluted Shares Outstanding
TTM
38,720,000n/a
Index Membership
n/a
Business Summary
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson\'s, Alzheimer\'s and schizophrenia.
no data available
Key Financials & Ratios (all figures TTM as per Mar 31, 2017, million USD, full statements further below)
Profit & Loss
Revenues 33n/a
Gross Profit 25n/a
Operating Income -311n/a
EBITDA -309n/a
Net Profit -309n/a
Balance Sheet
Cash and Cash Equivalents 469n/a
Receivables 8n/a
Total Current Assets 490n/a
PP&E 3n/a
Total Assets 503n/a
Accounts Payable 2n/a
Current Debt 0n/a
Total Current Liabilities 45n/a
Long-Term Debt 0n/a
Total Liabilities 45n/a
Total Equity 458n/a
Cash Flow
Depreciation & Amortisation 2n/a
Change in Working Capital 9n/a
Operating Cash Flow -240n/a
Net Change in PP&E and Intangibles -2n/a
Investing Cash Flow -40n/a
Dividends Paid 0n/a
Financing Cash Flow 262n/a
Total Change in Cash -18n/a
Free Cash Flow -303n/a
Profitability Ratios
Gross Margin 77.5%n/a
Operating Margin -954.7%n/a
Net Profit Margin -948.9%n/a
Return on Equity -67.6%n/a
Return on Assets -61.5%n/a
Per Share Figures
Basic EPS -2.61n/a
Diluted EPS n/a
Sales per Share 0.28n/a
Book Value per Share 3.86n/a
FCF per Share -2.56n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio -13.55n/a
Price to Sales Ratio 128.56n/a
Price to Book Value 9.16n/a
Price to Free Cash Flow -13.82n/a
Valuation Metrics
EV/EBITDA -12.46n/a
EV/Sales 118.08n/a
Book to Market Value 0.11n/a
Other Ratios
Current Ratio 1,082.0%n/a
Liabilities to Equity Ratio 9.9%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
6
42
2
5
1
0
0
17
Sales & Services Revenue
0
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
0
Cost of revenue
0
0
0
0
0
0
-3
-4
Cost of Goods & Services
0
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
0
Gross Profit
6
42
2
5
1
0
-2
13
Other Operating Income
0
0
0
0
0
0
0
0
Operating Expenses
-52
-27
-25
-26
-39
-93
-162
-286
Selling, General & Administrative
-10
-6
-8
-7
-13
-33
-88
-186
Selling & Marketing
0
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
0
Research & Development
-42
-21
-17
-19
-27
-61
-74
-99
Depreciation & Amortization
0
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
0
Operating Income (Loss)
-45
15
-23
-21
-38
-93
-165
-273
Non-Operating Income (Loss)
0
0
0
0
0
1
0
3
Interest Expense, net
0
0
0
0
0
1
0
3
Interest Expense
0
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
0
0
0
Pretax Income (Loss), Adjusted
-45
15
-23
-21
-38
-92
-164
-270
Abnormal Gains (Losses)
0
0
0
0
0
0
0
0
Acquired In-Process R&D
0
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
0
Pretax Income (Loss)
-45
15
-23
-21
-38
-92
-164
-270
Income Tax (Expense) Benefit, net
0
0
0
0
0
0
0
-1
Current Income Tax
0
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-45
15
-23
-21
-38
-92
-164
-271
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-45
15
-23
-21
-38
-92
-164
-271
Minority Interest
0
0
0
0
0
0
0
0
Net Income
-45
15
-23
-21
-38
-92
-164
-271
Preferred Dividends
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-45
15
-23
-21
-38
-92
-164
-271
Remarks
restated on Mar 6, 2012 n/a
calculated values,
restated on Mar 12, 2013 n/a
calculated values,
restated on Feb 27, 2014 n/a
calculated values,
restated on Feb 26, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
Balance SheetBS data quality: 98% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
37
31
108
186
322
215
529
Cash & Cash Equivalents
n/a
7
7
58
12
62
102
164
Short Term Investments
n/a
30
24
50
174
261
113
365
Accounts & Notes Receivable
n/a
0
0
0
0
0
0
6
Accounts Receivable, Net
n/a
0
0
0
0
0
0
6
Notes Receivable, Net
n/a
0
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
0
Inventories
n/a
0
0
0
0
0
0
4
Raw Materials
n/a
0
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
0
Other Short Term Assets
n/a
1
1
1
3
2
4
9
Prepaid Expenses
n/a
1
1
1
2
1
2
8
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
1
1
2
1
Total Current Assets
n/a
38
32
109
188
325
219
548
Property, Plant & Equipment, Net
n/a
0
0
0
1
1
2
3
Property, Plant & Equipment
n/a
0
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
0
Other Long Term Assets
n/a
0
0
0
0
0
1
10
Intangible Assets
n/a
0
0
0
0
0
0
7
Goodwill
n/a
0
0
0
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
0
0
0
0
0
1
3
Total Noncurrent Assets
n/a
1
0
0
1
1
3
13
Total Assets
n/a
38
32
109
189
325
222
561
Liabilities and owners' equity
Payables & Accruals
n/a
5 5191000
5 5464000
6 5514000
7 6924000
16 15834000
22 21902000
40 39941000
Accounts Payable
n/a
2 1972000
2 1960000
1 1375000
0 372000
2 2016000
2 1672000
4 3912000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
3 3219000
4 3504000
4 4139000
7 6552000
14 13818000
20 20230000
36 36029000
Short Term Debt
n/a
0 78000
0 32000
0 0
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
1 690000
1 669000
0 434000
0 55000
0 0
0 0
3 2644000
Deferred Revenue
n/a
1 690000
1 669000
0 434000
0 55000
0 0
0 0
3 2644000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
6 5959000
6 6165000
6 5948000
7 6979000
16 15834000
22 21902000
43 42585000
Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
3 2747000
3 2587000
18 17658000
0 8000
0 135000
0 232000
0 157000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
3 2623000
3 2587000
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
0 124000
0 0
18 17658000
0 8000
0 135000
0 232000
0 157000
Total Noncurrent Liabilities
n/a
3 2747000
3 2587000
18 17658000
0 8000
0 135000
0 232000
0 157000
Total Liabilities
n/a
9 8706000
9 8752000
24 23606000
7 6987000
16 15969000
22 22134000
43 42742000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
353 353282000
370 370224000
453 452700000
588 587751000
808 807641000
862 862337000
1,452 1452284000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-324 -324106000
-347 -346871000
-368 -367720000
-406 -405668000
-498 -498143000
-663 -662586000
-934 -933979000
Other Equity
n/a
1 512000
0 9000
0 4000
0 48000
0 -9000
0 11000
0 106000
Equity Before Minority Interest
n/a
30 29688000
23 23362000
85 84984000
182 182131000
309 309489000
200 199762000
518 518411000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
30 29688000
23 23362000
85 84984000
182 182131000
309 309489000
200 199762000
518 518411000
Total Liabilities & Equity
n/a
38 38394000
32 32114000
109 108590000
189 189118000
325 325458000
222 221896000
561 561153000
Remarks restated on n/a restated on Mar 6, 2012 n/a restated on Mar 12, 2013 n/a restated on Feb 27, 2014 n/a restated on Feb 26, 2015 n/a restated on Feb 29, 2016 n/a restated on Feb 28, 2017 n/a restated on May 9, 2017 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-45
15
-23
-21
-38
-92
-164
-271
Net Income
0
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Depreciation & Amortization
1
1
0
0
0
0
1
2
Non-Cash Items
3
1
3
2
7
17
38
55
Stock-Based Compensation
0
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
0
Change in Working Capital
28
-28
0
-2
-1
9
4
4
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
0
Cash from Operating Activities
-14
-11
-20
-22
-32
-66
-122
-210
Change in Fixed Assets & Intangibles
0
0
0
0
-1
0
-2
-2
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Net Change in Long Term Investment
9
-1
6
-26
-125
-87
150
-252
Decrease in Long Term Investment
0
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
0
0
-8
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
0
Cash from Investing Activities
9
-1
6
-26
-126
-87
148
-262
Dividends Paid
0
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
-1
0
0
0
0
0
0
14
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
2
1
14
98
112
204
15
519
Increase in Capital Stock
2
1
14
98
112
204
15
519
Decrease in Capital Stock
0
0
0
0
0
0
0
0
Other Financing Activities
0
0
0
0
0
0
0
1
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
0
Cash from Financing Activities
1
0
14
98
112
204
15
534
Net Cash Before Disc. Operations and FX
-3
-11
0
51
-46
50
40
61
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
0
Net Cash Before FX
-3
-11
0
51
-46
50
40
61
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
0
Net Changes in Cash
-3
-11
0
51
-46
50
40
61
Remarks
restated on Mar 6, 2012 n/a
calculated values,
restated on Mar 12, 2013 n/a
calculated values,
restated on Feb 27, 2014 n/a
calculated values,
restated on Feb 26, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
restated on Feb 28, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo